Pro 2013-006 (Announcement of Resolutions of the 9th Session of the 8th Board of Directors of Jianfeng Group)
Release time:
2020-08-05
Securities Code: 600668 Securities Abbreviation: Jianfeng Group No.: Lin 2013-006
Zhejiang Jianfeng Group Co., Ltd.
Resolution Announcement of the 9th Meeting of the 8th Board of Directors
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
On February 20, 2013, Zhejiang Jianfeng Group Co., Ltd. issued a notice to hold the ninth meeting of the eighth board of directors by fax, e-mail, telephone, and personal delivery. On February 26, 2013, the meeting was held as scheduled by means of communication. The company currently has nine directors, all of whom participated in this meeting. The related directors, Mr. Jiang Xiaomeng and Mr. Du Zihong, avoided voting on some proposals, which complied with the provisions of the Company Law and the Articles of Association, and the resolutions made were legal and effective. The meeting passed the following resolutions:
1. deliberated and passed "Proposal on Determining the Issuance Method, Guarantee Arrangement and Placement Arrangement of Corporate Bonds to the Company's Shareholders"
According to the authorization of the Company's First Extraordinary General Meeting in 2013 and in combination with the Company's future capital demand and cash flow situation, the issuance method, guarantee arrangement and allotment arrangement to shareholders of this corporate bond are as follows:
1 , issuance method
After this corporate bond is approved to be issued, will be issued in installments of .
Voting result :__9__ votes in favor, __0__ votes against, __0__ abstentions.
2 , Guarantee Arrangement
Tianjin Tianshili Group Co., Ltd. provides full and unconditional irrevocable joint and several liability guarantee for this corporate bond. Mr. Jiang Xiaomeng and Mr. Du Zihong, affiliated directors of
, avoided voting on the bill.
Voting Result :__ 7 ___ Voted Yes, __0__ Voted No, __0__ Voted Abstaining.
3 , Placement Arrangement to Company Shareholders
This time, corporate bonds are publicly issued to public investors, and is not arranged to be placed to Company Shareholders Priority .
Voting Result :__ 9 __ Voted Yes, __0___ Voted No, __0__ Voted Abstaining.
II and deliberated and passed the "Proposal on Providing Counter-Guarantees to Corporate Bonds"
confirmed that Tianjin Tianshili Group Co., Ltd. (hereinafter referred to as Tianshili Group) will provide full unconditional irrevocable joint and several liability guarantee for this corporate bond; tianjin Di Shili Investment Holding Group Co., Ltd. (hereinafter referred to as Di Shili Holdings), a major shareholder of Tianshili Group, provides counter-guarantee in the form of guarantee to Tianshili Group within the scope of this guarantee liability.
The Company pledged its equity of Tianshili Group 20.76# to Tianshili Holdings, the counter-guarantor of the corporate bonds, as a counter-guarantee provided by the Company to Tianshili Holdings within the scope of its guarantee liability. Authorize the Chairman of the Company to sign all legal documents relating to the above guarantees and counter-guarantees.
# Mr. Jiang Xiaomeng and Mr. Du Zihong, affiliated directors of the 116, avoided voting on the bill.
Voting Results :__ 7 __ votes in favor, __0__ votes against, __0__ abstentions. For details of
, please refer to the Announcement of on Providing Counter-Guarantees to Corporate Bond Counter-Guarantees published on the same day.
hereby announce
Zhejiang Jianfeng Group Co., Ltd. Board of Directors
February 26, 2013
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page